

Tuberculosis Research Funding Trends, 2005–2022

FIGURE 1

Total TB R&D Funding, 2005–2022




FIGURE 2

Progress toward *Global Plan* TB Research Funding Targets




TABLE 1**Annual Funding versus Annual Funding Targets**

RESEARCH AREA	2022 FUNDING	2018–22 <i>GLOBAL PLAN</i> ANNUAL TARGET	2023–30 <i>GLOBAL PLAN</i> ANNUAL TARGET
Basic Science	\$170,668,450	\$400,000,000	\$800,000,000
Diagnostics	\$145,406,615	\$183,200,000	\$965,000,000
Drugs	\$352,073,344	\$1,360,000,000	\$2,007,500,000
Vaccines	\$144,078,297	\$613,400,000	\$1,250,000,000
Operational Research & Epidemiology	\$123,036,923	--	--
Infrastructure/Unspecified	\$99,703,407	--	--
Total	\$1,034,967,036	\$2,556,600,000	\$5,022,500,000

FIGURE 3

TB R&D Funding by Funder Type, 2022

Total: \$1,034,967,036




TABLE 2

Progress Toward Fair Share Funding Targets in 2022

Fair Share = spending at least 0.1% of overall R&D expenditures on TB R&D

RANK	COUNTRY	2022 FUNDING	FAIR SHARE TARGET	PERCENT OF TARGET MET IN 2022
1	United States	\$436,073,634	\$444,500,000	98%
2	Germany*	\$36,093,374	\$99,700,000	36%
3	United Kingdom	\$32,682,386	\$40,400,000	81%
4	India	\$24,162,920	\$46,500,000	52%
5	South Korea	\$22,853,436	\$64,000,000	36%
6	France*	\$20,084,103	\$55,400,000	36%
7	Australia	\$13,894,959	\$21,200,000	66%
8	Canada	\$13,581,440	\$25,300,000	54%
9	Italy*	\$10,427,256	\$27,500,000	38%
10	Japan	\$8,120,185	\$154,900,000	5%
11	Spain*	\$7,909,472	\$20,799,869	38%
12	Sweden*	\$5,720,111	\$13,700,000	42%
13	Netherlands*	\$4,991,442	\$15,100,000	33%
14	Switzerland	\$4,948,543	\$13,400,000	37%
15	Brazil	\$4,735,865	\$35,000,000	14%
16	South Africa	\$4,206,545	\$4,600,000	91%
17	Ireland*	\$3,269,509	\$3,300,000	99%
18	Denmark*	\$2,718,640	\$7,500,000	36%
19	Belgium*	\$2,668,488	\$10,900,000	24%
20	Finland*	\$2,384,144	\$7,100,000	34%
21	New Zealand	\$1,397,953	\$1,800,000	78%
22	Peru	\$1,061,794	\$420,000	253%
23	Singapore	\$746,036	\$8,400,000	9%
24	Malaysia	\$738,818	\$9,807,000	8%
25	Norway	\$688,332	\$5,300,000	13%
26	Philippines	\$655,254	\$700,000	94%

Table includes countries that reported more than \$500,000 in TB R&D expenditures to TAG.

* 2022 funding for EU Member States (third column) includes a proportional share of total TB R&D spending by the European Commission mechanisms (EDCTP, EC, AMR | IMI) equal to the member state's "total national contributions" to the general EU budget in fiscal year 2022.

FIGURE 4

TB R&D Funding by Funder Type, 2018–2022 (in Millions)




TABLE 3

Top 20 Funders of TB Research, 2022

RANK	FUNDER	FUNDER TYPE	2022 FUNDING	2021 FUNDING
1	U.S. National Institutes of Health (U.S. NIH)	P	\$376,925,735	\$354,793,943
2	Bill & Melinda Gates Foundation	F	\$154,020,527	\$113,449,327
3	Unitaid	M	\$40,200,000	\$51,429,969
4	U.S. Agency for International Development (USAID)	P	\$37,435,817	\$30,000,620
5	Company X	C	\$37,151,321	\$21,736,349
6	AMR Accelerator/Innovative Medicines Initiative	P	\$32,475,079	\$31,116,653
7	Otsuka Pharmaceutical	C	\$27,643,679	\$23,701,770
8	Wellcome	F	\$26,452,024	\$11,849,984
9	European Commission	P	\$23,928,183	\$30,537,224
10	Indian Council of Medical Research (ICMR)	P	\$20,411,604	\$16,481,610
11	European and Developing Countries Clinical Trials Partnership (EDCTP)	P	\$17,516,947	\$29,289,139
12	U.S. Centers for Disease Control and Prevention (U.S. CDC)	P	\$17,420,159	\$25,894,931
13	Anhui Zhifei Longcom Biopharmaceutical Co.	C	\$15,766,810	\$4,145,802
14	U.K. Foreign, Commonwealth & Development Office (FCDO)	P	\$14,868,102	\$11,795,771
15	Korea Ministry of Health and Welfare	P	\$12,610,681	\$10,086,394
16	German Federal Ministry of Education and Research (BMBF)	P	\$11,513,871	\$17,505,028
17	Oxford Immunotec	C	\$11,200,000	\$12,000,000
18	Global Affairs Canada	P	\$8,457,130	\$11,167,884
19	U.K. Medical Research Council (U.K. MRC)	P	\$7,999,909	\$11,560,248
20	KfW Development Bank with BMBF	P	\$6,927,358	\$6,349,327

C = Corporation/Private Sector; F = Foundation/Philanthropy; M = Multilateral; P = Public-Sector R&D Agency

FIGURE 5

TB R&D Funding by Research Area, 2022

Total: \$1,034,967,036





FIGURE 6

TB R&D Funding by Research Area, 2018–2022 (in Millions)



Note: Data for years 2005–2017 not shown.

FIGURE 7

Basic Science: \$170,668,450




FIGURE 8

Diagnostics: \$145,406,615




FIGURE 9

Drugs: \$352,073,344




FIGURE 10

Vaccines: \$144,078,297




FIGURE 11

Operational Research & Epidemiology: \$123,036,923




FIGURE 12

Infrastructure/Unspecified: \$99,703,407




FIGURE 13

Pediatric TB R&D Funding by Research Area, 2022

Total: \$87,203,757




FIGURE 14

Pediatric TB R&D Funding, 2018–2022 (in Millions)




TABLE 4

Top 15 Pediatric TB R&D Funders, 2022

RANK	FUNDER	FUNDER TYPE	2022 FUNDING
1	U.S. National Institutes of Health (U.S. NIH)	P	\$23,219,071
2	Unitaid	M	\$16,100,000
3	U.S. Agency for International Development (USAID)	P	\$15,944,620
4	Bill & Melinda Gates Foundation	F	\$11,199,999
5	European and Developing Countries Clinical Trials Partnership (EDCTP)	P	\$6,022,933
6	Australian Department of Foreign Affairs and Trade (DFAT)	P	\$2,605,155
7	Company X	C	\$1,900,000
8	Wellcome	F	\$1,278,397
9	U.S. Centers for Disease Control and Prevention (U.S. CDC)	P	\$1,250,000
10	Australian National Health and Medical Research Council	P	\$1,034,594
11	Brazilian Ministry of Health	P	\$1,014,960
12	U.K. Medical Research Council (U.K. MRC)	P	\$913,477
13	Qure.ai	C	\$750,000
14	L'Initiative	P	\$470,905
15	South Africa Medical Research Council	P	\$452,247
	Other funders with expenditures <\$450,000		\$3,047,399
	Total		\$87,203,757

C = Corporation/Private Sector; F = Foundation/Philanthropy; M = Multilateral; P = Public-Sector R&D Agency

TABLE 5**New 0.15% Fair Share Targets: Select Examples**

COUNTRY	0.15% FAIR SHARE TARGET
United States	\$1,209,019,500
European Union*	\$706,095,690
Japan	\$265,442,184
Germany	\$229,848,390
South Korea	\$179,425,934
United Kingdom	\$135,141,551
France	\$115,428,470
India	\$88,082,100
Italy	\$61,409,810
Brazil	\$54,473,250
Canada	\$51,678,755
Spain	\$41,324,967
Netherlands	\$37,621,472
Australia	\$36,085,950
Sweden	\$31,461,153
Switzerland	\$29,838,551
Denmark	\$16,028,201
Finland	\$13,588,908
Norway	\$12,867,956
Ireland	\$8,494,199
South Africa	\$7,721,810
New Zealand	\$4,816,424
Philippines	\$1,726,350

* The EU fair share target includes spending by EU member states.

Note: TAG will begin tracking spending against 0.15% fair share targets in FY2023.